Company intelligence / Profile preview

Karyon Bio

Dallas, Texas, United States

Ownership: Private
Development stage: Other

Overview

Karyon Bio is a preclinical-stage biotechnology company focused on developing novel small molecule therapeutics for hormone-driven cancers. The company specializes in targeting protein-protein interactions between nuclear receptors and their oncogenic co-regulators, a space previously considered undruggable. Their lead research programs target the interaction between the androgen receptor and PELP1 to treat castration-resistant prostate cancer. By utilizing a proprietary peptidomimetic-based discovery platform, Karyon Bio aims to provide new treatment options for patients who have exhausted standard hormonal therapies.

Therapeutic areas: Oncology
Modalities: Small moleculePeptidomimetics
Industry: Biotech

Partnerships

UT Southwestern Medical Center

Beyond the preview

Go deeper on Karyon Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karyon Bio.

Explore the full profile